Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial

BACKGROUND: Animal and cellular studies support the importance of autophagy inhibition in lymphangioleiomyomatosis (LAM). In a cohort of subjects with LAM, we tested the hypothesis that treatment with sirolimus and hydroxychloroquine (an autophagy inhibitor) at two different dose levels is safe and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chest
Hauptverfasser: El-Chemaly, Souheil, Taveira-Dasilva, Angelo, Goldberg, Hilary J., Peters, Elizabeth, Haughey, Mary, Bienfang, Don, Jones, Amanda M., Julien-Williams, Patricia, Cui, Ye, Villalba, Julian A., Bagwe, Shefali, Maurer, Rie, Rosas, Ivan O., Moss, Joel, Henske, Elizabeth P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American College of Chest Physicians 2017
Schlagworte:
Diffuse Lung Disease
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026235/
https://ncbi.nlm.nih.gov/pubmed/28192114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2017.01.033
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge